Macro Intl Peer Comparison

BSE: 512600

₹81.00

₹0.40 (0.50%)

As on 28-Aug-2026 11:31IST

Market cap

₹356 Cr

Revenue (TTM)

₹170 Cr

P/E Ratio

36.5

P/B Ratio

1.1

Div. Yield

0 %

Edit

	Macro Intl	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	356	35,504	29,856	16,593	15,506
Revenue (₹ Cr)	170	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	9.74	1,018.97	497.77	603.02	270.18
Net Margin (%)	5.71	10.47	20.72	22.63	23.29
RoE (%)	5.25	21.30	28.49	19.61	14.45
Price to Earnings	36.55	35.10	59.98	27.52	56.31
Price-To-Book	1.06	6.77	14.77	4.76	7.48

Income Statement (₹ Cr)

	Macro Intl	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	170.18	9,683.45	2,371.81	2,590.40	1,108.39
Total Income	170.35	9,730.84	2,402.61	2,664.23	1,159.90
Total Expenditure	155.14	7,739.53	1,608.91	1,753.71	720.01
EBITDA	15.05	1,943.92	762.90	836.69	388.38
Depreciation	0.75	425.10	98.11	78.88	74.78
EBIT	14.30	1,518.82	664.79	757.81	313.60
Interest	1.44	148.45	26.33	5.43	0.26
Other Income	0.17	47.39	30.80	73.83	51.50
Exceptional Items	0.00	-27.85	0.00	-25.66	-3.28
Profit before Tax	13.03	1,389.91	669.26	800.55	361.56
Provision for Tax	3.30	370.94	171.48	197.53	91.39
Profit after Tax	9.74	1,018.97	497.77	603.02	270.18

	Macro Intl	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	327.16	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	0.00	-7.58	0.00	0.00	2.51
Non-Current Liabilities	1.29	723.57	345.47	142.73	50.51
Current Liabilities	71.12	3,912.24	710.20	508.04	169.08
Total Liabilities	63.34	8,121.73	2,179.88	3,753.59	2,034.25

	Macro Intl	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	292.62	3,392.16	1,290.62	1,321.38	957.22
Current Assets	103.26	5,612.10	1,483.13	2,649.36	1,250.11
Total Assets	63.34	8,121.73	2,179.88	3,753.59	2,034.25
Total Debt*	13.27	730.70	136.01	0.00	0.38
Net Current Assets	32.15	1,699.86	772.93	2,141.33	1,081.04
Contingent Liabilities	--	393.94	8.97	4.82	3.91

	Macro Intl	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	-12.52	851.71	317.40	391.52	244.52
Cash Flow from Investing Activities	-7.81	-94.00	-298.16	-615.65	-159.99
Cash from Financing Activities	3.29	-813.96	24.96	-6.23	-98.77
Net Cash Inflow / Outflow	-17.04	-56.25	44.21	-230.35	-14.24

	Macro Intl	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	34.78	22.49	23.45	25.50	29.62
ROE (%)	5.25	21.30	28.49	19.61	14.45
ROA (%)	4.21	11.42	19.48	16.31	12.66
EBIT Margin (%)	8.40	15.68	28.03	29.25	28.29
Net Margin (%)	5.71	10.47	20.72	22.63	23.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Macro Intl	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	122.71	18.36	78.33	7.93	-6.72
EBIT Growth (%)	8.14	30.43	303.07	19.88	-26.64
Net Profit Growth (%)	4.39	32.39	182.61	21.66	-24.38
EPS Growth (%)	-38.81	36.68	277.72	25.42	-21.99
Book Value Growth (%)	38.27	50.94	18.89	20.94	18.74

	Macro Intl	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	14.16	34.53	60.55	26.77	55.81
Price / Book Value	1.05	6.80	14.91	4.78	7.48
Dividend Yield (%)	0.00	0.19	0.14	0.37	0.51
EV/EBITDA	24.23	18.59	39.30	18.99	38.85
Market Cap (₹ Cr)	74.72	20,327.45	15,494.53	13,228.83	17,537.35

	Macro Intl	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.00	0.05	0.09	0.00	0.00
Short term debt to equity ratio	0.35	0.11	--	--	0.00
Current Ratio	1.45	1.43	2.09	5.21	7.39
Quick Ratio	1.05	0.82	1.37	3.85	5.46
Interest Coverage	10.07	10.36	26.41	148.49	1,386.30

	Macro Intl	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	42.49	26.46	22.82	41.42	41.52
Asset Turnover	0.74	1.09	0.93	0.70	0.52
Receivable days	123.54	87.83	85.17	132.12	132.49
Inventory Days	44.94	78.64	90.97	102.08	68.07
Payable days	84.55	174.97	137.94	133.54	123.94
Cash Conversion Cycle	83.93	-8.50	38.21	100.66	76.63

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.